|Bid||12.45 x 1200|
|Ask||12.60 x 900|
|Day's range||12.24 - 13.12|
|52-week range||4.74 - 18.48|
|Beta (5Y monthly)||2.49|
|PE ratio (TTM)||N/A|
|Earnings date||23 Feb 2022 - 28 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||19.91|
Participating with me today are CEO Jon Stonehouse; CFO Anthony Doyle; Chief Commercial Officer Charlie Gayer; Chief Medical Officer Dr. Three quarters of the way into 2021, and this has been an amazing year of execution for our company.
Shares of BioCryst (NASDAQ: BCRX), a biopharmaceutical company, are falling after the company reported third-quarter earnings results. The FDA approved BioCryst's first drug, Orladeyo, for patients with hereditary angioedema last December. Independent new drug launches have a terrible tendency to miss expectations, so the stock market is extra jumpy about revenue figures right now.
BioCryst (BCRX) delivered earnings and revenue surprises of -10.00% and 8.59%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?